skip to content
Primary navigation


Drug - Adempas® (riociguat) [Bayer HealthCare Pharmaceuticals Inc.]

March 2014

Therapeutic area - Pulmonary arterial hypertension (PAH); Chronic thromboembolic pulmonary hypertension (CTEPH)

Approval criteria

  • Patient has a diagnosis of PAH OR
  • Patient has a diagnosis of CTEPH

Quantity limit

Quantity limit = 102 tablets (all strengths).

Background information

Adempas is a soluble guanylate cyclase (sGC) stimulator indicated for the treatment of adults with Pulmonary Arterial Hypertension (PAH) or Persistent/recurrent Chronic Thromboembolic Pulmonary Hypertension (CTEPH).

Females of reproductive potential: Exclude pregnancy before the start of treatment, monthly during treatment, and 1 month after stopping treatment. Prevent pregnancy during treatment and for one month after stopping treatment by using acceptable methods of contraception.


MHCP Provider Call Center 651-431-2700 or 800-366-5411

back to top